Phase 2, randomized, double‐blind study of pracinostat in combination with azacitidine in patients with untreated, higher‐risk myelodysplastic syndromes
Guillermo Garcia‐Manero(The University of Texas MD Anderson Cancer Center), Gail J. Roboz(Cornell University), Rami S. Komrokji(Moffitt Cancer Center), Philip Kuriakose(Henry Ford Hospital), Yasmin Abaza(Northwestern University), Roger M. Lyons(Hematology Oncology Associates), Guillermo Montalban‐Bravo(The University of Texas MD Anderson Cancer Center), Richard Ghalie(MEI Pharma (United States)), Amy E. DeZern(Johns Hopkins University), James Essell(Oncology Hematology Care), Elias Jabbour(The University of Texas MD Anderson Cancer Center), Jesús G. Berdeja(Tennessee Oncology), Mikkael A. Sekeres(University of Miami), James A. Reeves(Sarah Cannon), Brian Heller(Southern Research Institute), Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), David Wright(Florida Cancer Specialists & Research Institute), Michael B. Maris(Colorado Blood Cancer Institute), Ralph V. Boccia(Center for Cancer and Blood Disorders), Farhad Ravandi(The University of Texas MD Anderson Cancer Center), Bertrand Anz(Tennessee Oncology), Sunil Babu(Fort Wayne Medical Institute)
Cited by 106
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
|Annals of Oncology|2020|1.5k